Developing a human recombinant IL-7 for the treatment of diseases that are caused by lymphopenia.
Cytheris is a biopharmaceutical company developing a human recombinant Interleukin 7 (IL-7) for the treatment of diseases that are caused by lymphopenia (low lymphocytes).
Discontinued operations in 2013.
Human Health
Industry
Biotech
Status
Realised